Brief: Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission

Neurosense Therapeutics

28/10/2024 12:53

Oct 28 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3
ALS
TRIAL AND NDA SUBMISSION
    * NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED FOR
NOV 6
FOR PHASE 3 ALS TRIAL
    * NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025,
WITH
REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026

Source text:  ID:nPnc9SmTqa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))